



www.genfit.com

GENFIT: CONVERSION INTO SHARES OF THE REMAINING OCA2012-2 BONDS

Lille (France), Boston (Massachusetts, United States), January 21st, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the conversion into shares of the remaining OCA2012-2 bonds, in keeping with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd.

In keeping with the 1st and 2nd resolutions of the Extraordinary Shareholders' Meeting held on December 18th, 2012 and with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd ("the Bondholder"), the Bondholder requested three new conversions on January 18th and January 21st, 2013 of a total of 35 OCA2012-2 bonds representing a value of €350,000.

The first two conversions performed on January 18th, 2013 of a total of 20 OCA2012-2 bonds resulted in the creation of a total of 65,042 new shares at a conversion rate of €3.07, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five trading days (January 11th - January 17th, 2013) prior to the conversion request.

The second conversion of 15 OCA2012-2 bonds into 48,340 new shares was performed at a conversion rate of €3.10, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five trading days (January 14th - January 18th, 2013) prior to the conversion request.

As a result of these three reserved share issues:

- The social capital of GENFIT has increased from €4,051,333.75 to €4,079,679.25;
- The number of shares representing the social capital of GENFIT has increased by 113,382, from 16,205,335 to 16,318,717 shares;
- The first €1 M installment of the bond loan agreement has been completely repaid.

Commenting on this announcement, Jean-François Mouney, Chairman and CEO of GENFIT, stated: *«The conversion of these first bonds took place in a very satisfactory manner, both in terms of their rapid implementation, thanks to the volumes observed since their issue, and also in terms of the impact on our share price. In the next few days, and in keeping with our convertible loan agreement, these good conditions will incite us to request the implementation of the second installment of the loan».*

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +33 1 7544 8740 / +336 8788 4726 – barabian@milestones.fr